BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer
Rhea-AI Summary
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announced a significant insider purchase by its Chairman and CEO, Jason Matuszewski.
On August 19, 2025, Matuszewski acquired 15,500 shares through two transactions: 2,500 shares at $6.28 and 13,000 shares at $6.51, totaling approximately $100,000. Following these purchases, his total ownership stands at 1,145,362 shares.
Positive
- CEO demonstrates confidence in company through $100,000 personal investment
- Significant insider ownership with CEO holding over 1.1 million shares
- Multiple purchase transactions showing sustained buying interest
Negative
- None.
News Market Reaction – BSEM
On the day this news was published, BSEM declined 3.09%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies.
Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately
For more information about the purchases, please visit the OTCID disclosure website HERE under Officer/Director/Affiliate Stock Transactions.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on X and LinkedIn.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.
Contact BioStem Technologies, Inc.:
Website: www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Adam Holdsworth, BioStem Director of Investor Relations
E-Mail: adam@biostemtech.com
Phone: 917-497-9287
Or
Gilmartin Group
Philip Trip Taylor, Principal
E-Mail: philip@gilmartinir.com
Phone: 415-937-5406
FAQ
How many shares did BioStem Technologies (BSEM) CEO purchase in August 2025?
What is the total stock ownership of BioStem Technologies CEO after the recent purchase?
At what price did the BSEM CEO purchase company shares?
What does BioStem Technologies (BSEM) specialize in?
